Inhibrx Biosciences to Present Phase 2 Trial Results for INBRX-106 in Head and Neck Cancer

Inhibrx Biosciences will host a live webcast presentation on Tuesday, September 8, at 5:00 a.m. Pacific Time, to unveil primary endpoint results from a Phase 2 clinical trial evaluating the safety and efficacy of INBRX-106, a hexavalent OX40 agonist, in combination with pembrolizumab, compared to pembrolizumab alone in patients with treatment-naïve, PD-L1 positive metastatic or unresectable recurrent Head and Neck Squamous Cell Carcinoma (HNSCC).

The company, a clinical-stage biopharmaceutical firm, will present data from the randomized and controlled HexAgon study. Investors can access the presentation via a web link or by dialing (1-888-880-3330) and providing the conference ID 6981384. The webcast will feature a slide presentation, available on the company’s investor section, and will be archived for 60 days following the event. Additionally, Inhibrx will update its corporate presentation on its website.

INBRX-106 is an innovative hexavalent agonist designed to target the OX40 (CD134) receptor, a costimulatory molecule on T-cells. By leveraging Inhibrx's proprietary single-domain antibody (sdAb) platform, the drug aims to achieve robust T-cell activation and survival, a challenge that traditional bivalent antibody approaches have failed to overcome.

Inhibrx Biosciences was established in January 2024 as a direct, wholly-owned subsidiary of Inhibrx, Inc. Prior to the sale of Inhibrx, Inc. and the INBRX-101 program to Sanofi S.A., Inhibrx Biosciences acquired certain corporate infrastructure and assets through a series of internal restructuring transactions. The company’s current pipeline includes ozekibart (INBRX-109) and INBRX-106, both utilizing multivalent formats optimized for target-specific agonist function.

This presentation is significant for investors and the medical community, as it may provide insights into the potential of INBRX-106 in treating a form of cancer that has a high unmet need.